A dvances in sequencing technologies have enabled the generation of large-scale genome, exome, and targeted-sequencing data for both research and clinical diagnostic purposes 1, 2 . These technologies output a list of variant calls and their genotypes, often in variant-call format (VCF) 3 , and benchmarking the accuracy of these calls is an essential part of analytical validation. This is especially important for clinical laboratories developing sequencing-based tests for medical care. Robust, sophisticated, and standardized benchmarking methods are therefore critical for the development, optimization, and comparison of sequencing, mapping, and variant-calling tools.
Efforts such as the Genome in a Bottle Consortium (GIAB) and Platinum Genomes have developed small variant truth sets, against which variant calls can be compared, for several well-characterized human genomes from publicly available cell lines and DNA [4] [5] [6] [7] . Another truth set was recently developed from a 'synthetic-diploid' mixture of two haploid hydatiform-mole cell lines not currently available in a public repository 8 . A framework for benchmarking non-complex small variant calls (that is, simple, isolated single nucleotide variations (SNVs), insertions, or deletions) in the exome has been developed as a web-based tool, called GCAT 9 . However, comparing variant calls from any particular sequencing pipeline to a truth set is not a trivial task. First, variants may be represented in multiple ways in the commonly used VCF [10] [11] [12] [13] and when comparing VCF files record by record, many of the observed differences can simply be different representations of the same variant. Second, definitions for performance metrics such as true positive (TP), false positive (FP), and false negative (FN), which are key for the interpretation of the benchmarking results, are not yet standardized. Finally, performance can vary across variant types and genomic regions, which inevitably increases the complexity of benchmarking results.
Two key performance metrics for assessing variant calling accuracy are sensitivity-the ability to detect variants that are known to be present or the absence of FNs-which we refer to as 'recall' , and specificity-the ability to correctly identify the absence of variants or the absence of FPs-for which we use the similar metric 'precision' 14 . The robustness of these metrics is particularly important for genome-sequencing applications in which novel sequence variants may be identified. Early professional guidelines call for the use of samples with and without known pathogenic variants to determine sensitivity and specificity, but this approach cannot predict performance for novel variants. To predict performance for novel variants, it is important to maximize the number and variety of variants that can be compared to a 'gold standard' to establish statistical confidence values for different types of variants and genome contexts, which can then be extrapolated to all sequenced bases [15] [16] [17] [18] . Guidelines were recently published for validating clinical bioinformatics assays 19 and highlighted not only the utility of reference materials for
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benchmarking variant calls, but also the importance of stratifying performance by variant type and genome context.
The aim of the Global Alliance for Genomics and Health (GA4GH) Benchmarking Team was to bring together participants from research institutes, technology companies, government agencies, and clinical laboratories, to standardize variant-calling benchmarking. Here we describe the available reference materials and tools to benchmark variant calls, and provide best practices for using these resources and interpreting benchmarking results. We standardized the variant benchmarking process in several ways (Fig. 1) . We reconciled methods (for example, rtgtools vcfeval 10 and hap.py xcmp 20 ) developed to compare callsets to assess the accuracy of variant and genotype calls independent of different representations of the same variant. We also represented primary performance metrics in the most commonly used binary classification form (that is, TP, FP, FN, and statistics derived from these) and standardized the calculation of performance metrics to make them more easily comparable across methods (for example, by hap.py quantify 20 ). Finally, we provide a framework whereby performance metrics can be stratified by variant type and genome context.
We discuss the technical challenges of, and present a solution to, accurately comparing VCF files and provide a strategy for benchmarking variant calls against available truth sets (for example, GIAB or Platinum Genomes). Overall, we develop a framework for standardizing and addressing some of the major challenges associated with benchmarking variant calls and summarize best practices for benchmarking in Supplementary Table 1 .
Results
Comparing variant calls to truth sets. We provide a strategy to benchmark single-sample query VCFs against existing truth sets. The inputs to this comparison are a truth callset (in VCF format), and a set of confident regions (in BED format) for the truth set. The confident regions indicate the locations of the genome where, when comparing to the truth callset, variants that do not match the truth callset should be FPs and variants missed in the truth callset should be FNs. Furthermore, our inputs include a query callset in VCF format, a reference genome sequence FASTA file (for example, GRCh37 or GRCh38), and optionally stratification regions to break out variantcalling performance in particular regions of the genome (for example, repetitive regions) or to restrict comparisons to a genomic subset (for example, exons/regions captured by targeted sequencing).
Variant representation. The primary challenge with comparing two VCF files is handling complex variant representations correctly. In a VCF file, we describe two haplotype sequences by means of REF/ALT pairs and genotypes. These variant calls do not always uniquely represent the same haplotype sequences. Alignments are not always unique even when using a fixed set of gap and substitution scores; different variant-calling methods may produce different variant representations. Although some of these differences can be handled using pre-processing of VCF files (for example, variant trimming and left-shifting), others cannot be fixed easily. As a result we cannot compare VCF files accurately by comparing VCF records and genotypes directly. Approaches were developed to standardize indel representation by means of left-shifting and trimming the indel alleles 21, 22 . These methods determine the left-most and right-most positions at which a particular indel could be represented in a VCF file (Fig. 2a) . These methods work well when considering each VCF record independently. However, when multiple VCF records are used to represent a complex haplotype, normalization methods can cause errors and more sophisticated comparison methods are required ( Fig. 2b-d) . Different types of variant-representation challenges are detailed in Supplementary Note 1. When benchmarking, these variantrepresentation differences can also give rise to different notions of giving partial credit for variant calls, such as when a method calls only one SNV in a multi-nucleotide variant (defined as multiple, adjacent SNVs) 23 . Our tools attempt to give partial credit when possible, and we generally recommend using vcfeval as the comparator to provide the most partial matches. Each of the comparison tools is described in Supplementary Note 2.
Matching stringencies and defining performance metrics. Owing to the inherent complexity of the human genome, and the challenge that genotype comparisons do not cleanly fall in a binary classification model, TP, FP, and FN can be defined in different ways. Our reference implementation for benchmarking uses a tiered definition of variant matches, a standardized VCF format for outputting matched variant calls (see Supplementary Note 3), and a common counting and stratification tool for variant type and genome context (see Supplementary Note 4). We consider three types of variant matches from most to least stringent: (1) 'genotype match' , for which only sites with matching alleles and genotypes are counted as TPs, (2) 'allele match' , for which any site with matching alleles is counted as TP, even if genotypes differ, and (3) 'local match' , for which any site in the query with a nearby truth variant is counted as a TP, even if alleles and genotypes differ. 'Genotype match' is used by our current tools to calculate TP, FP, and FN.
In Table 1 , we enumerate the types of matches that are clear TP, FP, and FN as well as various kinds of partial matches that may be considered TP, FP, and/or FN depending on the matching stringency, and how they are counted by our tools. Our tools calculate TP, FP, and FN requiring the genotype to match, but output additional statistics related to how many of the FPs and FNs are allele matches (FP. GT) or local matches (FP.AL). Table 2 includes examples of how different truth and query genotypes are counted as TP, FP, FN, FP.GT, and FP.AL. Note that we have chosen not to include true negatives (or consequently specificity) in our standardized definitions, because these metrics tend to be challenging to interpret (Methods)
We have implemented the comparison methods and metrics discussed above in hap.py; a standardized report that can be generated from the tabular output of the benchmarking workflow (see example in Supplementary Fig. 1 ). Definitions and formulas for all performance metrics, including derived metrics such as precision and recall, are detailed in the Methods and Supplementary Table 2 Benchmark callsets. Benchmarking of variant calls requires a specific genome and an associated set of calls that represent the 'right answers' for that genome. Such callsets have the property that they can be used as truth to accurately identify FPs and FNs. That is, when comparing calls from any sequencing method to this set of calls, at least half (and ideally more) of the putative FPs and FNs should be errors in the method being assessed. Because it is treated as the truth, this benchmark set will be referred to in this manuscript as the truth set, but other terms used for this include the 'gold-standard' set, the 'high-confidence' set, the 'reference callset, ' or 'benchmarking data. ' We describe three sources of benchmark callsets in detail in the Methods. (1) GIAB is an ongoing public-private-academic consortium hosted by the National Institute of Standards and Technology (NIST) to perform authoritative characterization of a small number of broadly consented and disseminated human genomes. Currently, five human genomes are available as NIST Reference Materials with benchmark small variant and reference calls for approximately 90% of GRCh37 and GRCh38 5, 7, 24 . (2) Platinum Genomes has also created a benchmarking dataset for small variants (SNVs and indels) using the 17-member pedigree (1,463) from Coriell Cell Repositories that includes the GIAB pilot sample NA12878/HG001 6 . This pedigree includes 11 children of the parents (NA12877 and NA12878), producing a fully phased dataset that confirms the accuracy of variant calls through genetic-inheritance patterns. A new draft merged GIAB-Platinum Genomes benchmark set for NA12878/HG001 is described in Supplementary Note 5 and Supplementary Fig. 2 . (3) A new 'synthetic-diploid' benchmark callset was created from long read assemblies of the CHM1 and CHM13 haploid cell lines, to benchmark small variant calls in regions difficult to analyze with short reads or in diploid genomes, which are currently excluded from the GIAB and Platinum Genomes high-confidence regions 8 . A current limitation is that CHM1 and CHM13 cell lines are not available in a public repository. It is important to understand how Note that representations include phasing information in these examples in which it is necessary to unambiguously describe the variant. If phasing was not described for these variants, it would be impossible to normalize their representations, but our sophisticated variant-comparison tools can determine that they could describe the same two haplotypes. 
each truth set was constructed and what biases and limitations it may have. The Methods summarize some limitations of the current truth sets, though these truth sets are likely to be improved in future versions as technologies improve
Lessons from PrecisionFDA challenges. The PrecisionFDA team held two challenges in 2016, with participants publicly submitting results from various mapping/variant-calling pipelines (https:// precision.fda.gov/challenges/). While both challenges asked participants to analyze short read whole-genome sequencing datasets, the first 'consistency' challenge used a sample with high-confidence calls already available (HG001/NA12878) and the second 'truth' challenge used a sample without high-confidence calls yet available (HG002 from GIAB, made available by GIAB upon the close of the challenge).
Note that both the truth sets and the comparison methodology in the truth challenge were newly introduced and under active development. The challenge results available on PrecisionFDA should be considered only as an initial evaluation, with the rich dataset resulting from the challenge inviting further exploration. Critical evaluation also calls for manual curation of a subset of FPs and FNs to ensure they are actually FPs and FNs and to understand their cause.
It is important to recognize that our benchmarking metrics indicate performance for the 'easier' variants and regions of the genome, so that precision and recall estimates are higher than if more difficult variants and regions were included. It is likely that some methods will perform worse than other methods for easier variants but perform better for harder variants (for example, methods using a graph reference or de novo assembly may do better calling in regions not assessed, like the major histocompatibility complex or large insertions, while not performing as well for easier variants because the methods are less mature). To gain insight into variantcall variability inside and outside the GIAB high-confidence regions for HG001, we compared two pipelines (DeepVariant and GATK) that had very high accuracy in the PrecisionFDA Challenge inside the high-confidence regions. In the high-confidence regions, when comparing these pipelines to each other (https://precision.fda.gov/ jobs/job-FJpqBP80F3YyfJG02bQzPJBj, link immediately accessible by requesting an account), they agreed on 99.7% of SNVs and 98.7% of indels. Outside the high-confidence regions (https://precision. fda.gov/jobs/job-FJpqJF80F3YyXqz6Kv8Q1BQK), they agreed with each other on only 76.5% of SNVs and 78.7% of indels. In tandem repeats longer than 200 bp (lowcmp_AllRepeats_gt200bp_gt95i-dentity_merged_slop5) and regions with 250 bp mapping ambiguity (map_l250_m0_e0) outside the high-confidence regions, they agreed on at most 60% of SNVs and indels. We expect this effect to be even greater when comparing short-read methods to new methods on the basis of long, single-molecule-sequencing reads.
Because larger changes such as structural variants are also generally excluded from the current high-confidence regions, it is important to recognize that large variants can contribute substantially to the number of bases that any individual is different from the reference. This might not be obvious when performing event-driven benchmarking. For example, the synthetic-diploid variant calls have about 26,000 insertions and deletions of at least 50 bp in size. While this number is small relative to the numbers of SNVs and small indels, the total number of bases inserted and deleted is more than 10 7 , greater than the total number of bases changed by the more numerous variants of less than 50 bp in size.
Interestingly, stringency of matching can also significantly influence performance metrics. For example, Table 3 shows how the number of FP indels for the assembly-based fermikit submission is much higher than the Real Time Genomics (RTG) submission when counting genotype errors as FPs, but the number of FPs is lower for fermikit when matching only the allele or performing distance-based matching. Exact genotype matching is most useful for many applications, for example, when interpreting variation in a clinical context, and this is why we developed sophisticated comparison tools to perform this matching. However, there are at least two use cases in which less stringent matching is useful in addition to genotype matching. (1) During methods development and optimization, it is often useful to know if most of the FPs are due to genotype or allele mismatch, so that the developer can focus on improving genotype and/or allele calling rather than on discovery. (2) If a laboratory will manually curate or confirm all detected variants, then calling the wrong variant near the true variant can be better than calling no variant if the true variant is determined upon curation or confirmation. Additional information about relative strengths and weaknesses of the pipelines could also be gained through stratification, as discussed in the next section.
Stratification illuminates challenging regions sequenced with and without PCR amplification. Our team has defined a large number of regions of different genome contexts (for example, GC content and repeats of different sizes and types) to enable users to stratify performance and understand strengths and weaknesses of a particular method. As an example of using stratification, we compare recall and precision in different genome contexts for wholegenome-sequencing assays with and without a PCR-amplification step. Table 4 shows that indel recall and precision are lower when using PCR amplification than when using PCR-free sequencing. Stratification highlights that this difference almost entirely results from PCR-related errors in homopolymers and tandem repeats, since performance is similar when excluding variants that occur within 5 bp of homopolymer sequences longer than 5 bp and tandem repeats longer than 10 bp. Performance in regions with low GC content is similar, but PCR results in lower SNV and indel recall in which GC content is greater than 85%.
Further stratification by type of repeat can illuminate particularly challenging genome contexts. For example, when sorting stratified genome contexts by recall, indels in 51-200-bp AT dinucleotide tandem repeats have substantially lower recall and precision than all other stratified genome contexts for both PCR and PCR-free results. Also, 86 out of 114 truth indels in 51-200-bp AT dinucleotide tandem repeats are compound heterozygous, and 89% fall outside the high-confidence regions, so our stratification and benchmarking methods help illuminate that these appear to be highly polymorphic and difficult variants to characterize. As discussed above, recall and precision are likely to be even lower outside the high-confidence regions in these stratified regions.
Discussion
The GA4GH Benchmarking Team has developed a suite of methods to produce standardized performance metrics for benchmarking small germline variant calls. These tools address challenges in standardizing metrics like recall and precision, comparing different representations of variant calls, and stratifying performance by variant Continually evolving benchmark data and methods are an important part of improving variant-calling performance. The performance metrics from current truth sets are useful for assessing the variants that methods detect similar to variant types and genome contexts present in the truth sets. However, some important types of variants probably have much lower accuracy owing to size and/or repetitive genome context and are outside the current truth set highconfidence regions 25 . New technologies will enable the characterization of increasingly difficult variants and genomic regions, which will require improved benchmarks and may lead to discovery of new variants of clinical and research interest that are currently challenging to detect. Simultaneously, characterization of reference materials may be improved through ongoing work by groups like GIAB.
Opportunities for further development of reference materials and benchmarking tools include structural variants and somatic variants. In addition to the genotype, allele, and local matching stringencies we describe for small variants, comparison tools for structural variants will need to consider stringencies for breakpoint matching, size predictions, and inserted-sequence predictions. Assessment of somatic variants also introduces distinct challenges compared with germline variants (for example, assessing accuracy of variant allele frequency). The ICGC-TCGA DREAM Somatic Mutation Calling (SMC) global consortium has been benchmarking both individual somatic variants and subclonal variation 26 . Moving forward, groups will also need to modify benchmarking strategies to address changes in the way the human genome itself is represented. Today the most common way of representing the human genome involves a set of linear chromosomes (for example, the most common usage of GRCh37). There are key advantages to nonlinear, graph representations of the genome, including ability to characterize large variants and complex variants [27] [28] [29] . The GRCh38 build of the human genome takes a step towards this by developing new ALT loci, which provide multiple distinct versions of specific complex regions of the genome 30 . These ALT loci are not fully used by most aligners or the benchmarking tools we describe, and their impact on benchmarking studies is largely unexplored and may require a variety of samples with differing ALT alleles. It is likely that the core representation of the genome will continue to evolve over time, and benchmarking tools will need to adapt to these changes. This work provides a framework for developing benchmarking tools capable of addressing new challenges in variant calling and other high-throughput measurement challenges.
online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability, and associated accession codes are available at https://doi.org/10.1038/ s41587-019-0054-x. [10] [11] [12] 20 . RTG developed the comparison tool vcfeval, which introduced the idea of comparing variants at the level of the genomic haplotypes that the variants represent as a way to overcome the problems associated with comparing complex variants, in which alternative yet equivalent variant representations can confound direct comparison methods 10 . Variant 'normalization' tools help to represent variants in a standardized way (for example, by left-shifting indels in repeats), but they demonstrated that 'variant normalization' approaches alone were not able to reconcile different representations of many complex variants. By contrast, global optimization permits evaluation of alternative representations that minimize the number of discrepancies between truth and test sets caused by differences in representations of the same variant. Similarly, VarMatch was developed to resolve alternative representations of complex variants, with additional ability to tune the matching parameters depending on the application 11 . Finally, hap.py includes a comparison tool xcmp to perform haplotype-based comparison of complex variants in addition to sophisticated functionality to stratify variant calls by type or region 20 . We use the hap.py framework with the vcfeval comparison tool in this work. More details about each comparison tool are in Supplementary Note 2. standardized, but accurate phasing can be critical, particularly when multiple heterozygous variants exist in a small region (for example, complex variants). Supplementary Fig. 3 shows two examples of nearby SNVs in coding regions that could be misinterpreted when not considering phasing.
Methods

Variant representation. A variety of approaches have been recently developed to address the challenges in variant representation
Matching stringencies.
Owing to the inherent complexity of the human genome, TPs, FPs, and FNs can be defined in different ways. Our reference implementation for benchmarking uses a tiered definition of variant matches, a standardized VCF format for outputting matched variant calls, and a common counting and stratification tool (see Supplementary Note 3). We consider the following types of variant matches from most to least stringent, with 'Genotype match' being used by our current tools to calculate TPs, FPs, and FNs:
• Genotype match: variant sets in truth and query are considered TPs when their unphased genotypes and alleles can be phased to produce a matching pair of haplotype sequences for a diploid genome. Each truth (and query) variant may be replayed onto one of two truth (or query) haplotypes. A maximal subset of variants that is replayed to produce matching haplotype sequences forms the TP variants, query variants outside this set are FPs, truth variants outside this set are FNs. The method only considers haploid or diploid samples but could be extended to higher ploidy. Enumerating the possible assignments for haplotype generation is computationally expensive. vcfeval solves this problem using global optimization methods supplemented with heuristic pruning. Genotype match statistics are the default TP, FP, and FN output by our tools. Genotype matching has been implemented in the hap.py tool xcmp and in vcfeval.
• Allele match: truth and query alleles are counted as TP_AM if they contain any of the same (trimmed and left-shifted) alleles. This method is more specific than local matching (for example, repeat expansions must be called with the correct length to get an allele match), but could also be susceptible to spurious mismatches when truth and query variant alleles are decomposed differently. Genotype mismatches (FP.GT in Table 1 ) are considered TPs in this matching method. We indicate allele matches in scenarios in which variants can be matched when ignoring the genotype. Allele match statistics (TP_AM, FP_AM, and FN_AM) can be calculated from the GA4GH outputs (which require genotypes to match): TP_AM = QUERY.TP + FP.GT, FP_ AM = QUERY.FP-FP.GT, and FN_AM = TRUTH.FN-FP.GT. Allele matching has been implemented in the hap.py tool scmp-somatic and in vcfeval with the --squash-ploidy option.
• Note that vcfeval --squash-ploidy and scmp-somatic differ. scmp-somatic checks if the VCF records give the same alleles after normalization and trimming. This will match alleles that overlap on the reference as long as they can be matched directly after left-shifting and trimming. When comparing somatic variant calls, this is probably the best option since technically, every variant could be on a different (low-frequency) haplotype. vcfeval --squash-ploidy does haplotype-based comparison but assumes all variants are homozygous and there is only one haplotype. This will match different representations unless they overlap on the reference (which is also possible using xcmp via the forcegt command line option in hap.py which changes the GTs before comparing).
• Local match: truth and query variants are counted as TP_LM if their reference span intervals are closer than a pre-defined local matching distance, that is, all yellow categories in Table 1 are considered TPs, including 'F' matches that are within a specified number of basepairs. This approach has previously been implemented 8, 20 . An advantage of this matching method is that it is robust towards representational differences. A drawback for many applications is that it does not measure allele or genotype accuracy. We use local matches as the lowest tier of matching to label variants which are close-by but cannot be matched with other methods. Local match statistics (TP_LM, FP_LM, and FN_LM) can be calculated from the GA4GH outputs (which require genotypes to match): TP_LM = QUERY.TP + FP.GT + FP.AL, FP_LM = QUERY. FP-FP.GT-FP.AL, and FN_LM = TRUTH.FN-FP.GT-FP.AL. If only local matching is required, this has been implemented in the hap.py tool scmpdistancebased.
• Phased-genotype match: a fourth, more stringent matching, which is not yet fully implemented in the GA4GH framework, requires phasing information to match. When VCF files specify phasing information, we can compare on a haplotype level: variants will only be matched if they produce matching haplotype sequences under phasing constraints. Both vcfeval and the xcmp method of hap.py support phased matching when both callsets include variants that are globally phased (that is, specify a paternal and maternal haplotype for each chromosome). To our knowledge, no current comparison method supports phasesets and local phasing to compare variants. Moreover, assessing phasing requires us to consider not only phasing-variant accuracy, but also completeness of phasing coverage. In our current methods we do not implement phased-genotype matching beyond the basic support provided by vcfeval and xcmp.
Defining TPs, FPs, and FNs. In Table 1 , we enumerate the types of matches that are clear TPs, FPs, and FNs as well as various kinds of partial matches that may be considered TPs, FPs, and/or FNs depending on the matching stringency, and how they are counted by our tools. Our tools calculate TPs, FPs, and FNs requiring the genotype to match, but output additional statistics related to how many of the FPs and FNs are allele matches (FP.GT) or local matches (FP.AL). Note that we have chosen not to include true negatives (or consequently specificity) in our standardized definitions. This is due to the challenge in defining the number of true negatives, particularly around complex variants. In addition, precision is often a more useful metric than specificity owing to the very large proportion of true negative positions in the genome. Another key question is how to count both matching and mismatching variant calls when they are differently represented in the truth dataset and a query. When representing MNPs as multiple SNVs, we may count one variant call for each SNV, or only one call in total for the MNP record. Similar considerations apply to counting complex records. We approach variant counting as follows:
• We count the truth and query VCF files separately. A set of truth records may be represented by a different set of query records.
• To get comparable recall, we count both TPs and FNs in their truth representation. When comparing different variant-calling results to the same truth set, these counts will be based on the same variant representation.
• Precision is assessed using the query representation of variants. We give a relative precision to the number of truth variants in query representation. If a variant caller is consistent about the way it represents variants, this approach mitigates counting-related performance differences.
• We implement a 'partial credit' mode in which we trim, left-shift and decompose all query variant calls before comparison. This resolves the MNV versus SNV comparison issues and also simplifies the variant types we use for stratification; rather than having a category of complex variant calls, which has results that are difficult to interpret, we account for every atomic indel and SNV call independently.
• Variants are stratified into a canonical set of types and subtypes (see Sup- plementary Note 4).
• When stratification regions are applied, we match variants by their trimmed reference span. If any part of a deletion overlaps the stratification region, it is counted as part of that stratum. Insertions receive special treatment by requiring both the base before and the base after to be captured. Importantly, this stratification is performed after comparison to deal appropriately with representation issues.
Note that we have chosen not to include true negatives (or consequently specificity) in our standardized definitions, owing to two key reasons. First, true negatives are challenging to define in whole-genome sequencing, as they will heavily depend on the variant type being evaluated. While SNV true negatives could be defined as one true negative per homozygous reference position, indels and complex variants complicate the definition of true negatives, particularly when in repetitive regions and when the two haplotypes have different indels or complex variants. Second, given the large proportion of homozygous reference positions in the genome, specificity generally is very close to one even for methods with many FPs, which can be misleading.
Benchmarking metrics report. To reconcile the comparison methods and metrics discussed above into a simple summary, we have implemented in hap. py a standardized report that can be generated from the tabular output of the benchmarking workflow 20 . This report displays the metrics we believe are most important in an accessible fashion (Tier 1 metrics), while also allowing to examine the data in more detail (Tier 2 metrics). An example for the metrics and plots displayed in such a report is shown in Supplementary Fig. 1 .
From the TP, FP, and FN counts defined in Table 1 We use the count of TPs on the basis of the query representation (QUERY. TP) to calculate precision, and we use the count of TPs on the basis of the truth representation (TRUTH.TP) to calculate recall, to account best for cases in which the truth may tend to split a complex variant into multiple variants and the query may combine them into a single variant, or vice versa. Definitions and formulas for all performance metrics are detailed in Supplementary Table 2 An alternative to precision is false positive rate (FPR) = FP per megabase (ref. 8 ). It can easily be obtained from GA4GH/hap.py extended csv by taking FP/1 × 10 6 ×Subset.Size (or Subset.IS_CONF.Size, the number of confident bases in each stratification region). Precision approximates the probability that a given query call is true, whereas FPR approximates the probability of making a spurious call. Note that we do not define 'true negatives' or 'specificity' because these are not cleanly applicable to genome sequencing. For example, there are an infinite number of possible indels in the genome, so there are an infinite number of true negatives for any assay.
In addition, the GA4GH Benchmarking framework is able to produce precision-recall curves, which are graphical plots that illustrate the performance of a variant quality score of a test callset as its discrimination threshold is varied, compared to the reference callset (see Supplementary Fig. 1b) . The curve is created by plotting the precision against the recall at various quality score threshold settings. Commonly used quality scores include QUAL, GQ (genotype quality), DP (depth of coverage), and machine-learning derived scores such as VQSLOD and AVR. Because some methods use multiple annotations for filtering, precisionrecall curves can be generated for a particular quality score either before or after removing filtered sites. Examining the precision-recall curves for various callsets has two main advantages. Firstly, it allows the user to consider how accuracy is affected through the precision-recall trade-off. Secondly, different callsets may have effectively selected different precision-recall trade-off criteria, so simply comparing full callset metrics may reflect more about the different trade-off points than the callsets themselves at some shared trade-off criteria.
Benchmark callsets. All of the truth sets described below use multiple callers and/ or technologies to alleviate bias towards any particular method, and our variant comparison tools are designed to minimize biases against callers that represent variants differently from the truth sets. Nevertheless, subtle biases are introduced in terms of which variants and regions are included in the truth and which are excluded from the high-confidence regions. For example, the current GIAB and Platinum Genomes calls are constructed from short reads and exclude regions difficult to access with short reads, and the current synthetic diploid calls exclude 1-bp indels owing to the relatively high indel error rate of long reads. Accurate reporting of truth set versions, variant types, fraction not assessed, and numbers and size of the confidence regions are also key to the successful interpretation of benchmarking results.
GIAB.
The GIAB is a public-private-academic consortium hosted by the NIST to perform authoritative characterization of a small number of human genomes to be used as benchmarks. GIAB published a benchmark set of small variant and reference calls for its pilot genome, NA12878, which characterized a high-confidence genotype for approximately 78% of the bases with sequence information (that is, bases that are not an 'N') in the human genome reference sequence (version GRCh37) 4 . Since this publication, GIAB has further developed integration methods to be more reproducible, comprehensive, and accurate, and has incorporated new technologies and analysis methods. The new integration process has been used to form benchmark small variant and reference calls for approximately 90% of GRCh37 and GRCh38 for NA12878, as well as a motherfather-son trio of Ashkenazi Jewish ancestry and the son in a trio of Chinese ancestry from the Personal Genome Project (v.3.3.2 available at ftp://ftp-trace. ncbi.nlm.nih.gov/giab/ftp/release/) 5, 7, 24 . The five GIAB-characterized genomes are available as NIST Reference Materials (RMs 8391, 8392, 8393, and 8398), which are extracted DNA from a single, homogenized, large growth of cells for each genome. These samples are also all available as cell lines and DNA from the Coriell Institute for Medical Research. The Personal Genome Project samples are also consented for commercial redistribution 24 , and several derived products are commercially available, including FFPE-preserved and in vitro mutated cell lines, or with DNA spike-ins with particular variants of clinical interest. GIAB is continuing to improve the characterization of these genomes to characterize increasingly difficult variants and regions with high-confidence.
Platinum Genomes. In addition to the benchmarking data produced by the GIAB, Platinum Genomes has also created a benchmarking dataset for small variants (SNVs and indels) using the 17-member pedigree (1,463) from Coriell Cell Repositories that includes the GIAB pilot sample NA12878/HG001 6 . Every sample of this pedigree was sequenced to approximately ×50 depth on an Illumina HiSeq2000 system. Variant calls were made from this data using different combinations of aligners and variant callers. This pedigree includes 11 children of the parents (NA12877 and NA12878), producing a fully phased dataset that allows validation of the accuracy of variant calls through genetic-inheritance patterns. The HiSeq2000 sequence data used to create these benchmarking calls can be obtained from the Database of Genotypes and Phenotypes (https://www.ncbi.nlm.nih.gov/ gap) under accession number phs001224.v1.p1. Additionally, the sequence data for six of the members of this pedigree are released through the European Nucleotide Archive (ENA; http://www.ebi.ac.uk/ena) under accession number ERP001960. The DNA and cell lines for all samples are available from the Coriell Institute for Medical Research, and DNA from a single, homogeneous batch of NA12878 is also available as NIST Reference Material 8398
Merged Platinum Genomes and GIAB. Since the two resources mentioned above constitute two different methods for generating truth callsets for NA12878, we have merged these into a single and more comprehensive dataset. Such a hybrid truth set can leverage the strengths of each input, namely the diversity of technologies used as input to GIAB and the robust validation-by-inheritance methodology employed by Platinum Genomes.
As a first pass, we have compared the callsets in NA12878 and identified the intersection as well as the ones unique to each (Supplementary Fig. 2 ). Next, starting from the union, we have used a modified version of the k-mer validation algorithm described in ref. 6 to validate the merged calls (Supplementary Note 5). This hybrid benchmark callset includes more total variants than either input set (67,000-333,000 additional SNVs and 85,000-90,000 additional indels), allowing us to assess more of the calls made by any sequencing pipeline without a loss in precision.
This new benchmarking set represents the first step towards a more comprehensive callset that includes both easy to characterize variants and those that occur in difficult parts of the genome. Despite this significant advance, there remain areas for continued improvement, such as adjudication between conflicting calls and the merging of confident regions. We will continue to develop this integration method to further expand the breadth of coverage of this hybrid truth set resource.
Currently, neither Platinum Genomes nor GIAB makes high-confidence calls on chromosome Y or the mitochondrial genome. In addition, GIAB currently has chromosome X calls only for females, but Platinum Genomes has haploid chromosome X calls for the male NA12877 as well. hap.py has an optional preprocessing step to guess male or female from the truth VCF. For male samples it converts haploid 1 GT calls on chromosomes X or Y to 1/1 so that they get compared correctly by xcmp. For vcfeval, haploid 1 GT calls are treated as the same as 1/1, so this conversion is not necessary.
Synthetic diploid.
A new synthetic-diploid benchmark callset was created from long-read assemblies of the CHM1 and CHM13 haploid cell lines, to benchmark small variant calls in regions difficult to analyze with short reads or in diploid genomes, which are currently excluded from the GIAB and Platinum Genomes high-confidence regions 8 . Because it is based on long reads, performance metrics are probably less biased toward any short-read sequencing technology or informatics method, and it enables benchmarking in regions that are difficult to map with short reads. However, because it currently contains some errors that were not corrected in the long reads, it requires a less stringent benchmarking methodology similar to the local-match method described below. It also excludes 1 bp indels from performance assessment since long-read assemblies contain 1-bp indel errors, and indels of greater than 50 bp because these are not analyzed. Therefore, it is currently not as useful for assessing accuracy of genotypes or accuracy of the exact sequence change predicted in the REF and ALT fields. When using GA4GH tools requiring genotypes to match, the majority of FPs and FNs may not be errors in the query callset, though work is underway to improve this. Nevertheless, it is likely to be complementary to the GA4GH benchmarking 1 nature research | reporting summary The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Software and code
Policy information about availability of computer code
Data collection
No software used for data collection.
Data analysis
All code for benchmarking developed for this manuscript are linked to from the GA4GH Benchmarking Team GitHub repository at https:// github.com/ga4gh/benchmarking-tools. The hap.py benchmarking toolkit is available at https://github.com/Illumina/hap.py.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
Raw sequence data used in the PrecisionFDA Truth Challenge were previously deposited in the NCBI SRA with the accession codes SRX847862 to SRX848317. Benchmark calls from Genome in a Bottle used in the PrecisionFDA challenges and in the examples in Table 3 and Table 4 are available at ftp://ftp-
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trace.ncbi.nlm.nih.gov/giab/ftp/release/. VCFs submitted to the PrecisionFDA Challenge and benchmarking results are available at https://precision.fda.gov/, where browse access is granted immediately upon requesting account.
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